Puma Biotechnology Operating Margin vs. Return On Asset

PBYI Stock  USD 3.23  0.09  2.87%   
Based on the key profitability measurements obtained from Puma Biotechnology's financial statements, Puma Biotechnology's profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Puma Biotechnology's ability to earn profits and add value for shareholders.

Puma Biotechnology Operating Profit Margin

0.13

As of now, Puma Biotechnology's Price Sales Ratio is increasing as compared to previous years. As of now, Puma Biotechnology's Net Income From Continuing Ops is increasing as compared to previous years. The Puma Biotechnology's current Net Income Applicable To Common Shares is estimated to increase to 2,415, while Accumulated Other Comprehensive Income is projected to decrease to (4.2 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.880.734
Fairly Up
Very volatile
For Puma Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Puma Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Puma Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Puma Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Puma Biotechnology over time as well as its relative position and ranking within its peers.
  

Puma Biotechnology's Revenue Breakdown by Earning Segment

Check out Your Equity Center.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.417
Earnings Share
0.47
Revenue Per Share
5.045
Quarterly Revenue Growth
0.435
Return On Assets
0.0973
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Puma Biotechnology Return On Asset vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Puma Biotechnology's current stock value. Our valuation model uses many indicators to compare Puma Biotechnology value to that of its competitors to determine the firm's financial worth.
Puma Biotechnology is regarded second in operating margin category among its peers. It is considered to be number one stock in return on asset category among its peers reporting about  0.35  of Return On Asset per Operating Margin. The ratio of Operating Margin to Return On Asset for Puma Biotechnology is roughly  2.82 . As of now, Puma Biotechnology's Operating Profit Margin is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Puma Biotechnology's earnings, one of the primary drivers of an investment's value.

Puma Return On Asset vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Puma Biotechnology

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.27 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Puma Biotechnology

Return On Asset

 = 

Net Income

Total Assets

 = 
0.0973
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Puma Return On Asset Comparison

Puma Biotechnology is currently under evaluation in return on asset category among its peers.

Puma Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Puma Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Puma Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Puma Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Puma Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4 K-4.2 K
Operating Income32.6 M34.3 M
Income Before Tax22.7 M23.8 M
Net Income21.6 M22.7 M
Net Income From Continuing Ops3.7 M3.9 M
Non Operating Income Net Other-10.5 M-10 M
Total Other Income Expense Net-10 M-10.5 M
Net Income Applicable To Common Shares2.3 K2.4 K
Income Tax Expense1.1 M1.1 M
Net Interest Income-10.8 M-11.4 M
Interest Income2.4 M1.5 M
Change To Netincome21.7 M20.6 M
Net Income Per Share 0.46  0.48 
Income Quality 1.44  1.51 
Net Income Per E B T 0.95  0.94 

Puma Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Puma Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Puma Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Puma Biotechnology's important profitability drivers and their relationship over time.

Use Puma Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Puma Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Puma Biotechnology Pair Trading

Puma Biotechnology Pair Trading Analysis

The ability to find closely correlated positions to Puma Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Puma Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Puma Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Puma Biotechnology to buy it.
The correlation of Puma Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Puma Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Puma Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Puma Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Puma Biotechnology position

In addition to having Puma Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Moderate Funds Thematic Idea Now

Moderate Funds
Moderate Funds Theme
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:
Check out Your Equity Center.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project Puma Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Puma Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Puma Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential Puma Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Puma Biotechnology investors may work on each financial statement separately, they are all related. The changes in Puma Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Puma Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.